arrow
B

Bin-Yan Zhong

Zhejiang Cancer Hospital
H指数:21
被引数:1,970

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TACE plus donafenib and immune checkpoint inhibitors for intermediate HCC (CHANCE2410 study): a propensity score matching analysis

TACE联合多纳非尼和免疫检查点抑制剂治疗中位HCC(CHANCE2410研究):一项倾向性评分匹配分析

2026-06-160
OAAI
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)

卡瑞利珠单抗和安罗替尼联合或不联合经动脉化疗栓塞作为晚期肝细胞癌的一线治疗(CHANCE2311)

2026-03-310
PRE
Decoding tumor heterogeneity with imaging biomarkers predicts response to TACE plus immunotherapy and targeted therapy in HCC (CHANCE2204)

使用影像生物标志物解码肿瘤异质性可预测TACE联合免疫治疗和靶向治疗在HCC中的疗效(CHANCE2204)

2025-11-013
PRE
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213)

在联合免疫治疗和靶向治疗后,纵向身体组成可识别恶病质的肝细胞癌 (CHANCE2213)

2024-11-270
OA
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as fi rst-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
2024-06-0117
OAAI